LPL Financial
BCAX

LPL Financial’s Bicara Therapeutics BCAX Stock Holding History

LPL Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
14,685
+579
+4% +$12.9K ﹤0.01% 5137
2026
Q1 		$281K Sell
14,106
-177
-1% -$3.05K ﹤0.01% 5230
2025
Q4 		$240K Sell
14,283
-14
-0.1% -$239 ﹤0.01% 5322
2025
Q3 		$226K Buy
+14,297
New +$160K ﹤0.01% 5273

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LPL Financial's BCAX Position: Q2 2026 in Review

LPL Financial increased its Bicara Therapeutics (BCAX) stake by 4.1% in Q2 2026, buying an estimated $12.9K and bringing the position to 14,685 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #5137.

LPL Financial first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • LPL Financial held 14,685 shares of Bicara Therapeutics worth $436K as of Q2 2026.
  • LPL Financial bought 579 Bicara Therapeutics shares in Q2 2026, an estimated $12.9K.
  • Bicara Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5137 holding.
  • LPL Financial first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.